Radiopharm Theranostics Ltd. announced interim results from its U.S. Phase 2b clinical imaging trial of RAD 101 in patients with brain metastases. According to the company, 92% of evaluable patients (11 out of 12) achieved concordance with MRI imaging, meeting the primary endpoint of the study. RAD 101, a novel small-molecule imaging agent targeting fatty acid synthase (FASN) and radiolabelled with Fluorine-18, demonstrated significant and selective tumor uptake in suspected or recurrent brain metastases. The interim data have been presented by the company, and a webinar is scheduled to discuss the findings. Radiopharm Theranostics also indicated plans to initiate a pivotal study by the end of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001144791-en) on December 15, 2025, and is solely responsible for the information contained therein.